MCID: UTR011
MIFTS: 42

Uterine Corpus Serous Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Uterine Corpus Serous Adenocarcinoma

MalaCards integrated aliases for Uterine Corpus Serous Adenocarcinoma:

Name: Uterine Corpus Serous Adenocarcinoma 12 15
Uterine Papillary Serous Carcinoma 12
Endometrial Serous Adenocarcinoma 71
Uterine Serous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5750
NCIt 49 C27838
UMLS 71 C1336921

Summaries for Uterine Corpus Serous Adenocarcinoma

Disease Ontology : 12 A uterine corpus cancer that is characterized histologically by papillae with fibrovascular cores, marked nuclear atypia, psammoma bodies and cilia.

MalaCards based summary : Uterine Corpus Serous Adenocarcinoma, also known as uterine papillary serous carcinoma, is related to endometrial adenocarcinoma and primary peritoneal carcinoma. An important gene associated with Uterine Corpus Serous Adenocarcinoma is PPP2R1A (Protein Phosphatase 2 Scaffold Subunit Aalpha), and among its related pathways/superpathways are ERK Signaling and Toll-like Receptor Signaling Pathway. The drugs Sirolimus and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include breast, thyroid and ovary, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Uterine Corpus Serous Adenocarcinoma

Diseases related to Uterine Corpus Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 189)
# Related Disease Score Top Affiliating Genes
1 endometrial adenocarcinoma 30.7 TP53 PTEN KRAS ERBB2
2 primary peritoneal carcinoma 30.6 TP53 ERBB2 BRCA1
3 in situ carcinoma 30.3 TP53 PTEN ERBB2 BRCA1
4 ovarian serous carcinoma 30.1 WT1 TP53 KRAS ERBB2
5 endometrial hyperplasia 30.0 TP53 PTEN KRAS ARID1A
6 papillary serous adenocarcinoma 29.9 WT1 TP53 KRAS BRCA1
7 papillary adenocarcinoma 29.9 TP53 KRAS ERBB2 BRCA1
8 hereditary breast ovarian cancer syndrome 29.9 TP53 PTEN KRAS BRCA1
9 adenocarcinoma 29.7 TP53 PTEN POLE PIK3CA KRAS ERBB2
10 cervical cancer 29.4 TP53 PTEN PIK3CA ERBB2 BRCA1 AURKA
11 gastrointestinal stromal tumor 29.2 WT1 TP53 PTEN KRAS ERBB2
12 wilms tumor 1 29.1 WT1 TP53 KRAS FBXW7 ERBB2
13 endometrioid ovary carcinoma 29.1 TP53 PTEN PPP2R1A POLE PIK3CA KRAS
14 lynch syndrome 28.9 TP53 PTEN POLE PIK3CA KRAS BRCA1
15 carcinosarcoma 28.6 WT1 TP53 PTEN PPP2R1A POLE PIK3CA
16 uterine carcinosarcoma 28.3 TP53 PTEN PPP2R1A POLE PIK3CA KRAS
17 serous cystadenocarcinoma 28.3 WT1 TP53 PTEN PPP2R1A PIK3CA KRAS
18 endometrial cancer 27.7 WT1 TP53 PTEN PPP2R1A POLE PIK3CA
19 ovarian cancer 26.9 WT1 TP53 SNCG PTEN PIK3CA KRAS
20 rare head and neck tumor 10.5 TP53 PIK3CA
21 thyroid hurthle cell adenoma 10.5 PTEN PIK3CA
22 gastric papillary adenocarcinoma 10.5 TP53 ERBB2
23 breast squamous cell carcinoma 10.4 TP53 PIK3CA ERBB2
24 papillary carcinoma 10.4
25 apocrine adenosis of breast 10.4 TP53 ERBB2
26 clear cell adenofibroma 10.4 PPP2R1A PIK3CA ARID1A
27 vulva squamous cell carcinoma 10.4 TP53 PPP2R1A PIK3CA
28 breast sarcoma 10.4 TP53 PIK3CA ERBB2
29 familiar ovarian carcinoma 10.4 PIK3CA BRCA1
30 polyploidy 10.4 TP53 AURKB
31 vulvar disease 10.4 TP53 PIK3CA ERBB2
32 breast juvenile papillomatosis 10.4 ERBB2 BRCA1
33 thyroid gland anaplastic carcinoma 10.4 TP53 PTEN PIK3CA
34 gallbladder adenocarcinoma 10.4 TP53 PIK3CA ERBB2
35 parotid gland cancer 10.4 TP53 ERBB2
36 comedo carcinoma 10.4 TP53 ERBB2
37 ovarian clear cell adenocarcinoma 10.3 TP53 PIK3CA ARID1A
38 clear cell adenocarcinoma 10.3 TP53 PIK3CA ARID1A
39 parameningeal embryonal rhabdomyosarcoma 10.3 TP53 PIK3CA FBXW7
40 pleomorphic adenoma carcinoma 10.3 TP53 ERBB2
41 anal squamous cell carcinoma 10.3 TP53 PIK3CA FBXW7
42 lobular neoplasia 10.3 TP53 ERBB2 BRCA1
43 ovarian carcinosarcoma 10.3 TP53 PPP2R1A PIK3CA ERBB2
44 thoracic benign neoplasm 10.3 TP53 ERBB2 BRCA1
45 breast benign neoplasm 10.3 TP53 ERBB2 BRCA1
46 brain stem glioma 10.3 TP53 PTEN PIK3CA
47 fallopian tube carcinosarcoma 10.3 WT1 TP53
48 fallopian tube endometrioid adenocarcinoma 10.3 ERBB2 CCNE1 ARID1A
49 breast fibroadenoma 10.3 TP53 ERBB2 BRCA1
50 vulva cancer 10.2 TP53 PTEN PIK3CA ERBB2

Graphical network of the top 20 diseases related to Uterine Corpus Serous Adenocarcinoma:



Diseases related to Uterine Corpus Serous Adenocarcinoma

Symptoms & Phenotypes for Uterine Corpus Serous Adenocarcinoma

GenomeRNAi Phenotypes related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 50)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.74 AURKA PIK3CA KRAS
2 Decreased viability GR00106-A-0 10.74 KRAS
3 Decreased viability GR00173-A 10.74 AURKB
4 Decreased viability GR00221-A-1 10.74 AURKA AURKB PIK3CA KRAS
5 Decreased viability GR00221-A-2 10.74 AURKA AURKB CDC42SE2 PIK3CA BRCA1 KRAS
6 Decreased viability GR00221-A-3 10.74 ERBB2 BRCA1
7 Decreased viability GR00221-A-4 10.74 AURKA AURKB CDC42SE2 ERBB2 PIK3CA
8 Decreased viability GR00231-A 10.74 AURKA
9 Decreased viability GR00301-A 10.74 BRCA1 KRAS
10 Decreased viability GR00381-A-1 10.74 KRAS
11 Decreased viability GR00402-S-2 10.74 AURKA AURKB CDC42SE2 ERBB2 PIK3CA BRCA1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.33 ARID1A
13 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.33 KRAS
14 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.33 POLE
15 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.33 BRCA1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.33 BRCA1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.33 PTEN
18 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.33 PTEN
19 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.33 PTEN
20 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.33 ERBB2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.33 ERBB2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.33 ARID1A BRCA1 ERBB2 KRAS POLE PTEN
23 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.33 ARID1A
24 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.33 KRAS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.33 BRCA1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.33 ARID1A
27 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.33 ARID1A
28 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.33 KRAS
29 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.33 POLE
30 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.33 ERBB2 POLE
31 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.33 BRCA1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.33 PTEN
33 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.33 KRAS
34 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.33 ERBB2 POLE
35 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.33 PTEN
36 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.33 ARID1A BRCA1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.33 KRAS
38 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.33 BRCA1 KRAS
39 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.33 ERBB2
40 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.33 ERBB2 KRAS POLE PTEN
41 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.33 BRCA1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.33 ARID1A
43 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.33 ERBB2 POLE
44 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.33 KRAS PTEN
45 Decreased viability in esophageal squamous lineage GR00235-A 10 ARID1A AURKA AURKB BRCA1 CCNE1 CHD4
46 Increased cell death HMECs cells GR00103-A-0 9.76 AURKA BRCA1 CHD4 FBXW7 PIK3CA PPP2R1A
47 Decreased cell proliferation GR00353-A 9.58 AURKA CDC42SE2 ERBB2
48 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 BRCA1 CCNE1 POLE PTEN TP53
49 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 AURKA AURKB BRCA1 CCNE1 POLE PTEN
50 Decreased sensitivity to paclitaxel GR00112-A-0 9.37 PTEN WT1

MGI Mouse Phenotypes related to Uterine Corpus Serous Adenocarcinoma:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.42 ARID1A AURKA AURKB BRCA1 CCNE1 CHD4
2 growth/size/body region MP:0005378 10.36 ARID1A AURKA AURKB BRCA1 CCNE1 CHD4
3 embryo MP:0005380 10.35 ARID1A AURKA AURKB BRCA1 CCNE1 CHD4
4 cardiovascular system MP:0005385 10.34 ARID1A AURKB BRCA1 CCNE1 ERBB2 FBXW7
5 mortality/aging MP:0010768 10.31 ARID1A AURKA AURKB BRCA1 CCNE1 CHD4
6 homeostasis/metabolism MP:0005376 10.29 ARID1A AURKB BRCA1 ERBB2 FBXW7 KIAA1324
7 hematopoietic system MP:0005397 10.27 ARID1A AURKA BRCA1 CCNE1 CHD4 FBXW7
8 endocrine/exocrine gland MP:0005379 10.26 ARID1A BRCA1 CCNE1 CHD4 ERBB2 FBXW7
9 immune system MP:0005387 10.23 ARID1A BRCA1 CCNE1 CHD4 FBXW7 KIAA1324
10 neoplasm MP:0002006 10.17 ARID1A AURKA AURKB BRCA1 CCNE1 ERBB2
11 integument MP:0010771 10.13 AURKB BRCA1 CCNE1 ERBB2 FBXW7 KRAS
12 muscle MP:0005369 9.97 ARID1A BRCA1 ERBB2 KRAS PIK3CA PTEN
13 no phenotypic analysis MP:0003012 9.86 ARID1A AURKA AURKB CHD4 KRAS PIK3CA
14 normal MP:0002873 9.85 ARID1A BRCA1 CCNE1 ERBB2 FBXW7 KRAS
15 reproductive system MP:0005389 9.73 ARID1A AURKB BRCA1 CCNE1 CLDN3 ERBB2
16 skeleton MP:0005390 9.28 ARID1A BRCA1 CCNE1 ERBB2 KIAA1324 KRAS

Drugs & Therapeutics for Uterine Corpus Serous Adenocarcinoma

Drugs for Uterine Corpus Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 5284616 6436030 46835353
2
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
3
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
4
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177 70789204
5
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
6 Estrogens Phase 2, Phase 3
7 Aromatase Inhibitors Phase 2, Phase 3
8 Anti-Infective Agents Phase 2, Phase 3
9 Hormone Antagonists Phase 2, Phase 3
10 Antibiotics, Antitubercular Phase 2, Phase 3
11 Anti-Bacterial Agents Phase 2, Phase 3
12 Antifungal Agents Phase 2, Phase 3
13 Immunosuppressive Agents Phase 2, Phase 3
14 Steroid Synthesis Inhibitors Phase 2, Phase 3
15 Estrogen Receptor Antagonists Phase 2, Phase 3
16 Estrogen Antagonists Phase 2, Phase 3
17 Hormones Phase 2, Phase 3
18
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
19
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
20
afatinib Approved Phase 2 850140-72-6, 439081-18-2 10184653
21
leucovorin Approved Phase 2 58-05-9 6006 143
22
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
23
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
24
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
25
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
26
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
28
MK-1775 Investigational Phase 2 955365-80-7, 501-36-0 24856436 445154
29 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
30 topoisomerase I inhibitors Phase 2
31 Topoisomerase Inhibitors Phase 2
32 Protein Kinase Inhibitors Phase 2
33 Mitogens Phase 2
34 Vitamin B Complex Phase 2
35 Vitamin B9 Phase 2
36 Folate Phase 2
37 Immunologic Factors Phase 2
38 Albumin-Bound Paclitaxel Phase 1, Phase 2
39 Antimitotic Agents Phase 2
40 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
41 Immunoconjugates Phase 2
42 Maytansine Phase 2
43 Anti-Inflammatory Agents Phase 2
44 Analgesics, Non-Narcotic Phase 2
45 Anti-Inflammatory Agents, Non-Steroidal Phase 2
46 Cyclooxygenase 2 Inhibitors Phase 2
47 Cyclooxygenase Inhibitors Phase 2
48 Antirheumatic Agents Phase 2
49 Analgesics Phase 2
50
Progesterone Approved, Vet_approved 57-83-0 5994

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
2 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
3 Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC) Completed NCT00022620 Phase 2 paclitaxel
4 A Phase I/II Study of Gleevec/Taxol in Patients With Newly Diagnosed Stage IIIC or IV or Recurrent (Any Stage) Uterine Papillary Serous Carcinoma (UPSC) Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
5 A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
6 Prospective, Non-randomised Phase 2 Clinical Trial of Carboplatin Plus Paclitaxel With Sequential Radical Pelvic Radiotherapy for Uterine Serous Papillary Cancer Completed NCT00147680 Phase 2 Paclitaxel, Carboplatin
7 Phase II Trial- Weekly Taxotere and Topotecan for Recurrent Ovarian, Primary Peritoneal, Endometrial and Uterine Cancers Completed NCT00231855 Phase 2 Topotecan and Taxotere
8 A Phase II Evaluation of Afatanib, an Irreversible Human Epidermal Growth Factor Receptor 2 (Her2/Neu) Tyrosine Kinase Inhibitor, in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma Recruiting NCT02491099 Phase 2 Afatinib
9 A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma Recruiting NCT03668340 Phase 2 AZD1775
10 Trial of Maintenance With Niraparib in Patients With Suboptimal Debulked Stage III, Stage IV or Platinum-sensitive Recurrent Uterine Serous Carcinoma Not yet recruiting NCT04080284 Phase 2 Niraparib
11 A Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial Cancer Not yet recruiting NCT03832361 Phase 2 IMGN853
12 A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin/Taxol Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma Not yet recruiting NCT04030000 Phase 1, Phase 2 Paclitaxel/Carboplatin
13 A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma Terminated NCT02112552 Phase 2 Paclitaxel;Carboplatin
14 A Pilot Phase II Trial of Celecoxib in Patients With Grade 2 or 3 Endometrioid-type, Clear Cell, and Papillary Serous Uterine Cancers Terminated NCT00231829 Phase 2 Celecoxib
15 A Phase I Study of Stereotactic Body Radiation Therapy for Patients With Limited Locoregional Recurrences of Ovarian and Uterine Serous Carcinoma Recruiting NCT03325634 Phase 1
16 Pre-operative Assessment and Post-Operative Outcomes of Elderly Women With Gynecologic Cancers Active, not recruiting NCT02315469
17 The Role of Synuclein-gamma (SNCG) in the Carcinogenesis of Uterine Papillary Serous Carcinoma Not yet recruiting NCT01344837
18 Racial Disparity in Prevalence and Survival Rates in Endometrial Cancer Terminated NCT00375804

Search NIH Clinical Center for Uterine Corpus Serous Adenocarcinoma

Genetic Tests for Uterine Corpus Serous Adenocarcinoma

Anatomical Context for Uterine Corpus Serous Adenocarcinoma

MalaCards organs/tissues related to Uterine Corpus Serous Adenocarcinoma:

40
Breast, Thyroid, Ovary, Lung, Brain, Cervix, Lymph Node

Publications for Uterine Corpus Serous Adenocarcinoma

Articles related to Uterine Corpus Serous Adenocarcinoma:

(show top 50) (show all 209)
# Title Authors PMID Year
1
Distant recurrence in a patient with polyp-confined stage IA serous endometrial carcinoma treated with adjuvant chemotherapy: A case report and review of literature. 61
31890830 2020
2
Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. 61
31833974 2020
3
Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression. 61
31906456 2020
4
Adjuvant chemotherapy in endometrial cancer. 61
31950214 2020
5
Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma. 61
31815745 2020
6
Metabolic syndrome affects the long-term survival of patients with non-endometrioid carcinoma of the uterine corpus. 61
31560127 2020
7
Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma. 61
31739992 2020
8
Breast metastases: A rare manifestation of advanced uterine serous carcinoma. 61
31656850 2019
9
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. 61
31839338 2019
10
The role of omentectomy in the surgical treatment of uterine serous carcinoma. 61
31517308 2019
11
Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma. 61
31228268 2019
12
Identification of ZYG11A as a candidate IGF1-dependent proto-oncogene in endometrial cancer. 61
31320996 2019
13
Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site. 61
31165997 2019
14
Synchronous renal and para-aortic metastasis in a uterine serous carcinoma: A case review and clinical considerations. 61
30740508 2019
15
Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation. 61
30896884 2019
16
Comparison of clinicopathologic and survival characteristics of high grade endometrial cancers; single center experience. 61
30122267 2019
17
Sectioning and extensively examining the fimbriated end (SEE-FIM) of the fallopian tube in routine practices, is it worth the effort? 61
30506766 2019
18
[Uterine serous carcinoma accompany with serous endometrial intraepithelial carcinoma and papillary proliferation of the endometrium: report of a case]. 61
30641649 2019
19
Adjuvant Pelvic Radiation "Sandwiched" Between Paclitaxel/Carboplatin Chemotherapy in Women With Completely Resected Uterine Serous Carcinoma: Long-term Follow-up of a Prospective Phase 2 Trial. 61
30371562 2018
20
Hysterectomy at the time of risk-reducing surgery in BRCA carriers. 61
30364812 2018
21
Characterization of Risk Factors and Timing of Venous Thromboembolism in Patients With Uterine Serous Carcinoma. 61
30303906 2018
22
Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management. 61
30613348 2018
23
Aging and uterine serous carcinoma. 61
29565096 2018
24
Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. 61
29941483 2018
25
BET inhibitors: Betting on improved outcomes in uterine serous carcinoma. 61
30464799 2018
26
Successful multidisciplinary treatment of uterine serous carcinoma in a patient who had previously undergone renal transplantation. 61
30122587 2018
27
Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report. 61
29977989 2018
28
Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel. 61
30174791 2018
29
Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it. 61
30265854 2018
30
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. 61
29584549 2018
31
Prognostic Factors of Uterine Serous Carcinoma-A Multicenter Study. 61
29621127 2018
32
High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma. 61
29940909 2018
33
MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. 61
29518404 2018
34
Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy. 61
29533019 2018
35
Saddle pulmonary embolus resulting in cardiovascular collapse requiring extracorporeal membrane oxygenation in a postoperative patient with endometrial cancer. 61
29915795 2018
36
Tumor lysis syndrome associated with docetaxel and carboplatin in a case with recurrent endometrial cancer. 61
29845102 2018
37
Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy. 61
29550183 2018
38
Malignant Endometrial Polyps in Uterine Serous Carcinoma: The Prognostic Value of Polyp Size and Lymphovascular Invasion. 61
29420362 2018
39
Synthetically lethal nanoparticles for treatment of endometrial cancer. 61
29203914 2018
40
ONC201 demonstrates anti-tumorigenic and anti-metastatic activity in uterine serous carcinoma in vitro. 61
30210923 2018
41
Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma. 61
28709703 2017
42
Immunohistochemical Study of ER, PR, Ki67 and p53 in Endometrial Hyperplasias and Endometrial Carcinomas. 61
28969139 2017
43
Factors prognostic of survival in advanced-stage uterine serous carcinoma. 61
28465008 2017
44
Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping. 61
28258415 2017
45
External pelvic and vaginal irradiation vs. vaginal irradiation alone as postoperative therapy in women with early stage uterine serous carcinoma: Results of a National Cancer Database analysis. 61
28511891 2017
46
Trends in Survival of Patients With Uterine Serous Carcinoma From 1988 to 2011: A Population-Based Study. 61
28562471 2017
47
Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. 61
27926776 2017
48
Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1). 61
28018954 2017
49
Uterine Serous Carcinomas Frequently Metastasize to the Fallopian Tube and Can Mimic Serous Tubal Intraepithelial Carcinoma. 61
27776011 2017
50
Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report. 61
28049106 2017

Variations for Uterine Corpus Serous Adenocarcinoma

Copy number variations for Uterine Corpus Serous Adenocarcinoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 52344 11 16200000 21700000 Copy number SAA Uterine serous papillary cancer

Expression for Uterine Corpus Serous Adenocarcinoma

Search GEO for disease gene expression data for Uterine Corpus Serous Adenocarcinoma.

Pathways for Uterine Corpus Serous Adenocarcinoma

Pathways related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 TP53 PTEN PPP2R1A KRAS ERBB2 CCNE1
2
Show member pathways
13.1 TP53 PPP2R1A PIK3CA KRAS CLDN3 CCNE1
3
Show member pathways
12.86 TP53 PTEN PIK3CA KRAS ERBB2 CCNE1
4
Show member pathways
12.85 TP53 PTEN PPP2R1A CHD4 CCNE1 BRCA1
5 12.82 TP53 PTEN PIK3CA KRAS ERBB2 CCNE1
6
Show member pathways
12.7 TP53 PTEN PIK3CA KRAS ERBB2
7
Show member pathways
12.7 TP53 PTEN PPP2R1A PIK3CA KRAS ERBB2
8
Show member pathways
12.68 TP53 POLE FBXW7 CCNE1 BRCA1
9
Show member pathways
12.61 TP53 PTEN PIK3CA KRAS ERBB2
10
Show member pathways
12.54 TP53 PTEN PIK3CA KRAS ERBB2 CCNE1
11
Show member pathways
12.49 TP53 PIK3CA KRAS ERBB2
12
Show member pathways
12.49 TP53 PTEN PIK3CA KRAS ERBB2
13 12.44 TP53 PPP2R1A CCNE1 BRCA1 AURKB AURKA
14
Show member pathways
12.44 TP53 PTEN PPP2R1A PIK3CA KRAS ERBB2
15
Show member pathways
12.42 TP53 PIK3CA KRAS ERBB2
16
Show member pathways
12.42 TP53 PTEN PIK3CA KRAS ERBB2 CCNE1
17 12.36 TP53 PTEN PIK3CA KRAS ERBB2 CCNE1
18
Show member pathways
12.35 TP53 PTEN CCNE1 BRCA1
19
Show member pathways
12.33 PPP2R1A PIK3CA KRAS CCNE1 AURKA
20 12.31 TP53 PTEN PIK3CA KRAS CCNE1
21 12.29 TP53 PIK3CA KRAS ERBB2
22 12.25 TP53 PIK3CA KRAS CHD4 CCNE1
23
Show member pathways
12.24 TP53 PTEN CCNE1 BRCA1
24
Show member pathways
12.22 TP53 PTEN PIK3CA KRAS ERBB2
25 12.18 PTEN KRAS ERBB2 AURKA
26 12.13 TP53 PTEN PIK3CA KRAS CCNE1
27
Show member pathways
12.12 PTEN PIK3CA KRAS ERBB2
28 12.1 TP53 PTEN KRAS BRCA1 AURKA
29 11.95 TP53 PTEN PPP2R1A PIK3CA KRAS
30 11.94 TP53 PTEN KRAS CCNE1
31 11.92 TP53 PTEN PIK3CA KRAS ERBB2
32 11.86 TP53 PTEN PIK3CA CCNE1
33 11.84 PTEN CCNE1 BRCA1
34 11.82 TP53 POLE CCNE1
35
Show member pathways
11.81 TP53 CCNE1 BRCA1
36 11.72 TP53 KRAS ERBB2
37 11.7 TP53 PIK3CA ERBB2 BRCA1
38 11.57 TP53 PTEN PIK3CA
39 11.49 TP53 PTEN BRCA1
40 11.49 TP53 PTEN PIK3CA KRAS ERBB2
41 11.47 TP53 CCNE1 BRCA1
42 11.3 TP53 CCNE1 BRCA1
43 11.26 PTEN PIK3CA KRAS
44 11.24 TP53 CCNE1 BRCA1
45 11.16 TP53 BRCA1 AURKB AURKA
46 11.01 TP53 CCNE1 BRCA1
47 10.99 TP53 PTEN PIK3CA FBXW7 ERBB2 BRCA1
48 10.36 TP53 CCNE1

GO Terms for Uterine Corpus Serous Adenocarcinoma

Cellular components related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.9 WT1 TP53 PTEN POLE FBXW7 CHD4
2 cytoplasm GO:0005737 9.53 WT1 TP53 SNCG PTEN PPP2R1A PIK3CA
3 chromosome passenger complex GO:0032133 8.96 AURKB AURKA

Biological processes related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 9.73 WT1 TP53 ERBB2 CHD4 BRCA1 ARID1A
2 heart development GO:0007507 9.67 WT1 TP53 PTEN ERBB2
3 regulation of protein stability GO:0031647 9.5 PTEN KRAS AURKA
4 regulation of signal transduction by p53 class mediator GO:1901796 9.35 TP53 CHD4 BRCA1 AURKB AURKA
5 androgen receptor signaling pathway GO:0030521 9.33 CCNE1 BRCA1 ARID1A
6 positive regulation of gene expression GO:0010628 9.17 WT1 TP53 PTEN KRAS ERBB2 CLDN3

Molecular functions related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.35 POLE KRAS ERBB2 AURKB AURKA
2 histone serine kinase activity GO:0035174 8.62 AURKB AURKA

Sources for Uterine Corpus Serous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....